A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma.

Magnus Lindskog,Anna Laurell,Anders Kjellman,Bohuslav Melichar,Jacek Niezabitowski,Pablo Maroto,Henryk Zieliński,Felipe Villacampa,Pierre Bigot,Zoltán Bajory,Omi Parikh,David Vázquez-Alba,Åsa Jellvert,Tibor Flaskó,Enrique Gallardo Diaz,Maria J. Ribal,Gunta Purkalne,Peter Suenaert,Alex Karlsson-Parra,Börje Ljungberg

A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma.

2020

11Background: Ilixadencel is a cell-based allogeneic off-the-shelf product aimed to prime anti-cancer immune response when injected intratumorally. The present randomized Phase II multicenter trial...

Keywords:

Renal cell carcinoma
Internal medicine
Cell
Sunitinib
Phases of clinical research
Multicenter trial
Oncology
Immune system
Medicine
Primer (molecular biology)
Pathology
cell based

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations